NL-OMON51372招募中不适用
A biomarker assessment study to investigate the influence of high-frequency chest wall oscillations on the clearance of cerebrospinal fluid biomarkers - Cerebrospinal fluid biomarker clearance
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Signed informed consent prior to any study-mandated procedure
- •2. Healthy male or female subjects, 18 to 50 years of age, inclusive at
- •3. Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and
- •with a minimum weight of 50 kg.
- •4. All women of childbearing potential must practice effective contraception
- •during the study.
- •5. Has the ability to communicate well with the Investigator in the Dutch
- •language and willing to comply with the study restrictions.
排除标准
- •1. Evidence of any active or chronic disease or condition that could interfere
- •with, or for which the treatment of might interfere with, the conduct of the
- •study, or that would pose an unacceptable risk to the subject in the opinion of
- •the investigator (following a detailed medical history, physical examination,
- •vital signs (systolic and diastolic blood pressure, pulse rate, body
- •temperature) and 12-lead electrocardiogram (ECG)). Minor deviations from the
- •normal range may be accepted, if judged by the Investigator to have no clinical
- •2. Clinically significant abnormalities, as judged by the investigator, in
- •laboratory test results (including hepatic and renal panels, complete blood
- •count, chemistry panel and urinalysis). In the case of uncertain or
- •questionable results, tests performed during screening may be repeated before
- •randomization to confirm eligibility or judged to be clinically irrelevant for
- •healthy subjects.
- •3. History of malignancy not deemed cured by their treating physician.
- •4. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab),
- •or human immunodeficiency virus antibody (HIV Ab) at screening.
- •5. Systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and
- •diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg at
- •6. Abnormal findings in the resting ECG at screening defined as:
- •a. QTcF> 450 or < 300 msec for men and QTcF> 470 or < 300 msec for women
- •b. Notable resting bradycardia (HR < 40 bpm ) or tachycardia (HR > 100 bpm)
- •c. Personal or family history of congenital long QT syndrome or sudden death;
- •d. ECG with QRS and/or T wave judged to be unfavourable for a consistently
- •accurate QT measurement (e.g., neuromuscular artefact that cannot be readily
- •eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T-
- •and U-waves, prominent U waves);
- •e. Evidence of atrial fibrillation, atrial flutter, complete branch block,
- •Wolf-Parkinson-White Syndrome, or cardiac pacemaker
- •7. Participation in an investigational drug or device study (last dosing of
- •previous study was within 90 days prior to first dosing of this study)
- •8. History of abuse of addictive substances (alcohol, illegal substances) or
- •current use of more than 21 units alcohol per week, drug abuse, or regular user
- •of sedatives, hypnotics, tranquillisers, or any other addictive agent
- •9. Positive test for drugs of abuse at screening. A retest may be performed at
- •the discretion of the investigator.
- •10. Alcohol will not be allowed from at least 24 hours before each visit,
- •including screening and follow-up
- •11. Smoker of more than 10 cigarettes per day prior to screening or who use
- •tobacco products equivalent to more than 10 cigarettes per day and unable to
- •abstain from smoking whilst in the unit.
- •12. Is demonstrating excess in caffeine consumption (more than eight cups of
- •coffee or equivalent per day)
- •13. Loss or donation of blood over 500 mL within three months (males) or four
- •months (females) prior to screening or intention to donate blood or blood
- •products during the study.
- •14. If a woman, pregnant, or breast-feeding, or planning to become pregnant
- •during the study.
- •15. For CSF sampling, any of the criteria below:
- •a. History of clinically significant hypersensitivity to local anesthetics that
研究者
相似试验
已完成
不适用
A study of cell signalling biomarkers in patients with tuberous sclerosisISRCTN62388748Aeovian Pharmaceuticals Inc.14
招募中
不适用
An observational study to determine biomarkers for prognosis of lung lesions in patients with polymyositis/dermatomyositis complicated by interstitial lung diseasePolymyositis/dermatomyositis complicated with interstitial lung disease (PM/DM-ILD)JPRN-UMIN000046198agasaki University125
已完成
不适用
Biomarker study; study to identify biomarkers for protein intake, a randomized, fully controlled feeding studyGeen aandoeningenUitscheiding van biomerkers na het eten van eiwit in het gezond menselijk lichaamBiomarkers of protein intakeNL-OMON36525Wageningen Universiteit25
尚未招募
2 期
An Observational Study To Relate Two Biological markers with Left Heart Pressure And Blood Concentration of A Drug Dobutamine In Patients Undergoing By Pass Heart SurgeryCTRI/2018/05/013554R SUBHASHINI
尚未招募
不适用
A retrospective study to explore the biomarkers in lung cancer immunotherapy, 2nd stage -irAE predictionung cancerJPRN-UMIN000051528ational Cancer Center Hospital East350